PT  - JOURNAL ARTICLE
AU  - Nuria A. Callejas
AU  - Amalia Fernández-Martı́nez
AU  - Antonio Castrillo
AU  - Lisardo Boscá
AU  - Paloma Martı́n-Sanz
TI  - Selective Inhibitors of Cyclooxygenase-2 Delay the Activation of Nuclear Factor κB and Attenuate the Expression of Inflammatory Genes in Murine Macrophages Treated with Lipopolysaccharide
AID  - 10.1124/mol.63.3.671
DP  - 2003 Mar 01
TA  - Molecular Pharmacology
PG  - 671--677
VI  - 63
IP  - 3
4099  - http://molpharm.aspetjournals.org/content/63/3/671.short
4100  - http://molpharm.aspetjournals.org/content/63/3/671.full
SO  - Mol Pharmacol2003 Mar 01; 63
AB  - The effect of rofecoxib, a selective cyclooxygenase-2 inhibitor, on inflammatory signaling has been investigated in elicited murine peritoneal macrophages. Macrophages treated with 10 μM rofecoxib exhibited an important inhibition in the early activation of nuclear factor κB (NF-κB) and the mitogen-activated protein kinase p38, the extracellular-regulated kinase p44, and the c-Jun N-terminal kinase. Moreover, this drug decreased the protein levels of nitric-oxide synthase-2 and cyclooxygenase-2 in lipopolysaccharide (LPS)-treated macrophages. Rofecoxib delayed and attenuated NF-κB activation, which impaired significantly the expression of κB-dependent genes. This drug and related coxibs did not affect cell viability and protected against LPS-induced apoptosis through the impairment of the inflammatory response. These data show an additional anti-inflammatory mechanism of selective cyclooxygenase-2 inhibitors through the attenuation of macrophage activation.